[Omalizumab: What have we learned after ten years of prescription?]. / Omalizumab : qu'avons-nous appris après 10ans d'utilisation ?
Rev Mal Respir
; 33(2): 117-27, 2016 Feb.
Article
in Fr
| MEDLINE
| ID: mdl-26346415
ABSTRACT
INTRODUCTION:
Omalizumab, an anti-immunoglobulin E monoclonal antibody, has now been used for ten years as an add-on therapy for severe adult atopic asthma, poorly controlled by high-doses inhaled steroids and long-acting beta-agonists.BACKGROUND:
This innovative therapy has been the first biotherapy used on a large scale in severe asthma. It has shown clinical benefits, especially in the prevention of severe exacerbation, with a satisfactory safety profile. Despite its cost, it is an interesting alternative to continuous oral steroids, which cause more long-term side effects. PERSPECTIVES After ten-years of prescription of omalizumab, we review here the mechanism of action, the benefits, the main side effects, the cost-effectiveness and also the alternative indications of this interesting molecule. We also consider the practicalities of using omalizumab, particularly the importance a rigorous assessment of its efficacy after 16 weeks of treatment, and possible future therapeutic indications.CONCLUSION:
Omalizumab has proven its efficacy in large randomized studies but also in real life practice in severe allergic asthma.Key words
Full text:
1
Collection:
01-internacional
Database:
MEDLINE
Main subject:
Drug Prescriptions
/
Asthma
/
Omalizumab
Type of study:
Clinical_trials
Limits:
Humans
Language:
Fr
Journal:
Rev Mal Respir
Year:
2016
Document type:
Article
Affiliation country:
France